Skip navigation
Explore
Sciety application settings
Home
Groups
Lists
Newsletter
About
Log In
Sign Up
Inhibition of a lower potency target drives the anticancer activity of a clinical p38 inhibitor
Debanjan Bhattacharjee
Jaweria Bakar
Surbhi P. Chitnis
Erin L. Sausville
Kumar Dilip Ashtekar
Brianna E. Mendelson
Kaitlin Long
Joan C. Smith
David E. Heppner
Jason M. Sheltzer
Read the full article
See related articles
Listed in
Rudd Lab JC
(RuddLab)
Log in to save this article
Abstract
No abstract available
Article activity feed
Version published to 10.1016/j.chembiol.2023.09.013
Oct 1, 2023
Version published to 10.1101/2022.10.16.512438v1 on bioRxiv
Oct 16, 2022
Related articles
A Suite of Biochemical and Cell-Based Assays for the Characterization of KRAS Inhibitors and Degraders
This article has 13 authors:
Medhanie Kidane
Rene M. Hoffman
Jennifer K. Wolfe-Demarco
Ting-Yu Huang
Chi-Ling Teng
Luis M. Gonzalez Lira
Jennifer Lin-Jones
Gabriel Pallares
Jane E. Lamerdin
Nicole B. Servant
Chun-Yao Lee
Chao-Tsung Yang
Jean A. Bernatchez
Computational modeling of drug response identifies mutant-specific constraints for dosing panRAF and MEK inhibitors in melanoma
This article has 13 authors:
Andrew Goetz
Frances Shanahan
Logan Brooks
Eva Lin
Rana Mroue
Darlene Dela Cruz
Thomas Hunsaker
Bartosz Czech
Purushottam Dixit
Udi Segal
Scott Martin
Scott A. Foster
Luca Gerosa
Discovery of the first-efficacious A
2A
R negative allosteric modulators for high adenosine cancer immunotherapies
This article has 11 authors:
Margot Boujut
Margaux Héritier
Aurélie Gouiller
Camille Süess
Alessandro Scapozza
Thibaut De Smedt
Maxime Guibert
Sébastien Tardy
Hesham Hamed
David Pejoski
Leonardo Scapozza
Site navigation links
Home
Groups
Lists
Newsletter
About
Log In
Sign Up